Table 2.
Distribution of subjects with first-line therapy and lines of therapy prescribed by year of mRCC diagnosis in Norwegian patients with mRCC
| Therapy | 2002
|
2003
|
2004
|
2005
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
|---|---|---|---|---|---|---|---|---|---|---|
| (n=139) | (n=118) | (n=149) | (n=136) | (n=155) | (n=175) | (n=176) | (n=178) | (n=227) | (n=225) | |
| First-line therapy, n (%) | 8 (5.8) | 9 (7.6) | 44 (29.5) | 37 (27.2) | 65 (41.9) | 90 (51.4) | 90 (51.1) | 95 (53.4) | 141 (62.1) | 163 (72.4) |
| Chemotherapy, n (%) | 1 (0.7) | 0 | 7 (4.7) | 0 | 3 (1.9) | 1 (0.6) | 1 (0.6) | 0 | 2 (0.9) | 2 (0.9) |
| Hydroxyurea, n | 1 | 0 | 7 | 0 | 3 | 1 | 1 | 0 | 2 | 2 |
| Cytokine therapy, n (%) | 4 (2.9) | 7 (5.9) | 27 (18.1) | 25 (18.4) | 27 (17.4) | 2 (1.1) | 1 (0.6) | 1 (0.6) | 1 (0.4) | 2 (0.9) |
| Interferon-α-2a, n | 3 | 5 | 15 | 18 | 22 | 0 | 1 | 1 | 1 | 2 |
| Interferon-α-2b, n | 1 | 2 | 12 | 7 | 5 | 2 | 0 | 0 | 0 | 0 |
| Targeted therapy, n (%) | 3 (2.2) | 2 (1.7) | 10 (6.7) | 12 (8.8) | 35 (22.6) | 87 (49.7) | 88 (50.0) | 94 (52.8) | 138 (60.8) | 159 (70.7) |
| Sunitinib, n | 3 | 2 | 8 | 9 | 29 | 78 | 85 | 93 | 130 | 138 |
| Sorafenib, n | 0 | 0 | 2 | 3 | 6 | 7 | 0 | 1 | 1 | 0 |
| Pazopanib, n | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 | 18 |
| Everolimus, n | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 3 |
| Axitinib, n | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| No therapy, n (%) | 131 (94.2) | 109 (92.4) | 105 (70.5) | 99 (72.8) | 90 (58.1) | 85 (48.6) | 86 (48.9) | 83 (46.6) | 86 (37.9) | 62 (27.6) |
| Line of therapy,a n (%) | ||||||||||
| First line | 8 (100) | 9 (100) | 44 (100) | 37 (100) | 65 (100) | 90 (100) | 90 (100) | 95 (100) | 141 (100) | 163 (100) |
| Second line | 1 (13) | 1 (11) | 11 (25) | 23 (62) | 30 (46) | 28 (31) | 40 (44) | 48 (51) | 70 (50) | 73 (45) |
| Third line | 0 | 0 | 7 (16) | 9 (24) | 12 (18) | 10 (11) | 22 (24) | 28 (29) | 34 (24) | 26 (16) |
| Fourth line | 0 | 0 | 2 (5) | 5 (14) | 4 (6) | 2 (2) | 8 (9) | 16 (17) | 17 (12) | 10 (6) |
| Fifth line | 0 | 0 | 0 | 3 (8) | 1 (2) | 0 | 4 (4) | 6 (6) | 8 (6) | 5 (3) |
| Sixth line | 0 | 0 | 0 | 2 (5) | 1 (2) | 0 | 2 (2) | 3 (3) | 4 (3) | 3 (2) |
| Seventh line | 0 | 0 | 0 | 1 (3) | 0 | 0 | 1 (1) | 3 (3) | 2 (1) | 2 (1) |
| Eighth line | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1) | 2 (2)b | 0 | 0 |
Notes:
a
Percentage calculated as the proportion of patients who received first-line therapy.
b
One patient received 11th-line therapy.
Abbreviation: mRCC, metastatic renal cell carcinoma.